Follistatin gene therapy for muscle growth: hype vs. reality

What did @theregendoc actually say?

The creator made several claims worth unpacking. They described follistatin as "a peptide that helps with strength" that "inhibits an enzyme called myostatin," said this therapy involves "one injection" that "lasts for about a year," and framed it as restoring youthful follistatin levels through gene delivery. They also called myostatin an enzyme, described the mechanism as a vector introducing a follistatin gene, and pulled Ozempic and insulin into the conversation as context for what peptides are.

The core argument: as you age, follistatin drops, myostatin runs unchecked, you lose muscle, and this therapy fixes that with a single shot that tells your body to produce more follistatin. That is the pitch. Now let us look at what actually holds up.

Does the science back this up?

Partially, but with serious caveats. Follistatin does inhibit myostatin signaling, and myostatin does suppress muscle growth. That part is well-established. What is not established is that a single off-label gene therapy injection in a clinical or telehealth setting is safe, durable, or approved for this use in humans.

The myostatin-follistatin axis has been studied for decades. Rodent and animal models consistently show that myostatin inhibition increases muscle mass (Lee, 2004, PNAS). Human trials have been more complicated. A 2015 study by Mendell et al. in Molecular Therapy tested follistatin gene delivery in Becker muscular dystrophy patients and saw modest functional improvements, but this was a disease population under strict trial conditions, not healthy aging adults. There are no large randomized controlled trials confirming safety or efficacy of follistatin gene therapy for age-related muscle loss in otherwise healthy people. The claim that it "lasts for about a year" is drawn from early trial data, but durability and dose responses in general populations remain unknown.

What did they get wrong (or right)?

Let us be specific. The creator got the general concept of the myostatin-follistatin relationship right. Follistatin does act as an inhibitor of myostatin, and myostatin does limit muscle hypertrophy. Credit where it is due.

But they got two things meaningfully wrong. First, they called myostatin an enzyme. It is not. Myostatin is a protein in the TGF-beta family, a signaling molecule, not an enzyme. That is a basic factual error. Second, the framing of this as a ready, accessible, one-and-done anti-aging tool glosses over the regulatory reality: follistatin gene therapy is not FDA-approved for any aging or performance indication. Administering it outside of a clinical trial context raises serious safety and legal questions. The creator did not mention any of that.

The Ozempic and insulin comparison to establish peptide credibility is a rhetorical move, not a scientific argument. Semaglutide's regulatory approval says nothing about the safety of experimental gene vectors.

What should you actually know?

Gene therapy using adeno-associated virus (AAV) vectors, which is the delivery mechanism implied here, carries real risks including immune responses, off-target gene expression, and unknown long-term effects. The FDA has approved AAV-based gene therapies for specific diseases, but not for general longevity or muscle optimization. The International Society of Gene and Cell Therapy has specifically cautioned against unregulated gene therapy offerings marketed to healthy individuals.

The "one injection, lasts a year" framing makes this sound like a simple peptide protocol. It is not comparable. You cannot un-inject a gene therapy if something goes wrong. That asymmetry of risk deserves more than a passing mention in a 60-second TikTok. If you are seeing this type of therapy promoted through a telehealth platform without a full informed consent process, oversight from a clinical trial, and transparent disclosure of experimental status, that is a red flag worth taking seriously.